Drug Profile
PUR 118
Alternative Names: PUR118Latest Information Update: 12 Apr 2016
Price :
$50
*
At a glance
- Originator Pulmatrix
- Class Anti-inflammatories; Antiasthmatics; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis; Influenza virus infections
Most Recent Events
- 12 Apr 2016 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in Germany (Inhalation)
- 12 Apr 2016 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
- 12 Apr 2016 Discontinued - Phase-I for Cystic fibrosis in United Kingdom (Inhalation)